Hemodialysis

Hemodialysis is a recurring setting in the medical history of hepatitis C virus infection, not merely a method of replacing lost kidney function. Patients receiving long-term treatment were recognized as a high-risk population soon after the virus was identified, and the dialysis unit became a crucial site for distinguishing past exposure from active infection, tracing transmission, enforcing infection-control practice, and evaluating survival and quality of life. The same treatment environment that sustains patients with advanced kidney disease therefore also exposes the practical consequences of a systemic infection that can affect the liver, immune system, and kidneys.

Definition and Clinical Setting

Hemodialysis provides maintenance renal replacement for patients whose kidney function has failed, placing them in repeated contact with dialysis stations, staff, equipment, blood products, and other patients. In the early period of hepatitis C recognition, this repeated exposure made the hemodialysis population particularly important to epidemiologic investigation. Hepatitis C virus infection was already understood as more than a liver disease: it could induce autoimmune, dermatological, and renal disorders, and its relationship with chronic kidney disease made nephrology, dialysis, and transplantation central fields for clinical guidance.

The epidemiology of infection in hemodialysis changed substantially after the identification of hepatitis C virus as the principal cause of non-A, non-B hepatitis in 1989. In the 1990s, patients undergoing hemodialysis had high prevalence and incidence in many western countries. The burden was initially associated partly with the regular transfusions historically used in this population, but several observations pointed beyond transfusion alone: prevalence correlated strongly with time on dialysis independently of transfusional burden, was higher in hemodialysis than in peritoneal dialysis or home hemodialysis, and remained substantial among patients who had never been transfused.

Hepatitis C Risk and Detection

The risk from transfused blood fell sharply as donor screening improved and erythropoiesis-stimulating agents became widely available. The estimated risk of post-transfusion hepatitis C declined from approximately 0.5% per blood unit in the 1980s to about 0.0001%, or one case per million blood units, in the United States, with comparable progress in other western countries. Attention consequently moved toward transmission within dialysis units, where blood handling and repeated procedures created opportunities for contamination if basic precautions were not consistently applied.

Diagnosis depends on separating exposure from active infection. Third-generation enzyme-linked immunosorbent assays detect anti-hepatitis C virus antibodies, but antibody positivity alone cannot establish ongoing viral replication. Active chronic infection requires both anti-hepatitis C virus antibodies and detectable hepatitis C virus RNA, with sensitive molecular assays reaching a threshold of roughly 15 IU/ml. This distinction is especially important in patients undergoing hemodialysis, whose long clinical histories may include prior exposure, resolved infection, or persistent viremia. Evaluation of an active infection must also consider hepatic injury and extrahepatic disease, including cryoglobulinemia-associated vasculitis.

The broader diagnostic framework includes assessment of fibrosis and of renal manifestations. Liver biopsy may be used, although noninvasive biochemical and morphological tests can avoid approximately half of biopsies and permit yearly follow-up of fibrosis in untreated patients. FibroScan measures liver stiffness, while other noninvasive indices contribute biochemical estimates. In kidney transplant candidates, screening is essential because up to one quarter of patients with active infection have advanced fibrosis despite otherwise well-compensated disease. In low-prevalence regions, initial enzyme immunoassay testing is followed by nucleic acid testing when antibodies are detected; in high-prevalence settings, nucleic acid testing should be the first-line test because a negative antibody assay cannot reliably exclude infection.

Prevention Within Dialysis Units

The prevention of nosocomial transmission rests on infection-control practice rather than on routine segregation of infected patients. The KDIGO workgroup concluded that dedicated dialysis machines for hepatitis C virus-infected patients are not recommended. Large prospective observational studies, including the Dialysis Outcomes and Practice Patterns Study and an Italian study, found that isolating infected patients in separate wards did not protect other patients after adjustment for confounding factors, including the prevalence of infection within the unit. Isolation was therefore not recommended as an alternative to strict precautions against bloodborne pathogens.

The practical rules are deliberately concrete. Staff should wash their hands with soap or antiseptic handwash and water before and after contact with a patient or equipment at the dialysis station; alcohol-based antiseptic gel is an acceptable alternative when hands are not visibly contaminated. Disposable gloves should be worn for patient care or contact with potentially contaminated surfaces and removed before leaving the station. Single-use items must be discarded after treating one patient. Reusable items must be disinfected or dedicated to one patient, and potentially contaminated surfaces must be cleaned after every session, using a stronger disinfectant when contamination is visible.

Where reuse of dialysers cannot be avoided, dialysers used for infected patients may be reused only when strict infection-control procedures are implemented and followed. Waste management is part of the same system, as are regular observational audits incorporated into performance reviews of dialysis units. The emphasis is thus not on a single barrier but on a chain of ordinary actions whose reliability determines whether a treatment station remains safe.

Liver Disease and Systemic Consequences

Hepatitis C-related liver disease is often clinically silent in patients receiving long-term hemodialysis. Asthenia, fatigue, and cognitive impairment may occur, but these symptoms are also common in the dialysis population regardless of serologic status and can therefore be overlooked. Biochemical abnormalities may provide additional clues: serum transaminases and gamma-glutamyl transpeptidase can be elevated, although the increase is sometimes modest. In a northern Italian cohort of 757 patients on long-term dialysis, gamma-glutamyl transpeptidase was higher in patients with hepatitis C virus and/or hepatitis B virus infection than in uninfected patients, but only 22% showed the relevant elevation.

Other laboratory findings have been linked to extrahepatic effects. Patients with hepatitis C virus infection on long-term dialysis have shown higher intact parathyroid hormone levels than uninfected patients, approximately 422 ± 423 compared with 338 ± 356 pg/ml, an observation associated with the concept of hepatic osteodystrophy. Clinicians may nevertheless discount such findings because dialysis patients commonly have arterial hypertension, gastrointestinal bleeding, anemia, vascular-access failure, and other competing conditions. Cirrhosis remains relatively uncommon in western dialysis registries, occurring in approximately 1.5% to 2% of patients, but its lower frequency does not eliminate the importance of chronic infection or its longer-term complications.

Hepatitis C virus can also produce systemic immune disease. It is the major cause of mixed cryoglobulinemia, a vasculitis that may involve arthralgia, arthritis, Raynaud phenomena, purpura, peripheral neuropathy, low complement levels, and kidney disease. Renal manifestations range from proteinuria and hematuria to reduced estimated glomerular filtration rate, acute nephritic syndrome, or nephrotic syndrome. Kidney disease may appear years after the first extrarenal signs, and the typical renal lesion is type I membranoproliferative glomerulonephritis, also called cryoglobulinemic glomerulonephritis.

Survival, Quality of Life, and Treatment Implications

Longitudinal studies have found an independent association between anti-hepatitis C virus positivity and reduced survival among patients receiving long-term hemodialysis. A meta-analysis of seven observational studies involving 11,589 patients estimated a relative risk of death of 1.34 for infected patients. Liver-related causes were especially prominent: hepatocellular carcinoma and cirrhosis were more frequent among antibody-positive patients, and the unadjusted relative risk of liver-related mortality was 5.89 compared with antibody-negative patients.

The cardiovascular evidence is more complex. In a prospective study of 94 dialysis patients, including 17 with hepatitis C virus infection, viremia was independently associated with high aortic stiffness, with an odds ratio of 9.7. Event-free survival curves for cerebrovascular and cardiovascular outcomes also differed according to hepatitis C virus RNA status, supporting a possible atherogenic role through metabolic syndrome and dyslipidemia. Yet the cited meta-analysis found no significant unadjusted association between hepatitis C virus infection and cardiovascular mortality, reporting a relative risk of 0.95. The contrast illustrates why the infection's overall mortality signal cannot be reduced to a single cardiovascular pathway.

Quality of life adds a less visible but clinically important dimension. In a study of 165 regular dialysis patients, 83 of whom were anti-hepatitis C virus positive, infection was independently associated with a lower mental component score on the 36-item Short Form health survey, with a coefficient of -3.423. No association was found with the physical component score. Depression may reflect the diagnosis and its long-term implications, or may arise alongside fatigue and cognitive impairment; hemodialysis itself independently increases the prevalence of depression. Whether antiviral treatment improves survival by improving quality of life, apart from changes in liver histology or virologic measures, remains uncertain, but patients with advanced liver disease may still gain meaningful benefit from treatment.

Therapeutic decisions have evolved with the understanding of viral replication. In the period described, treatment was based chiefly on pegylated interferon and ribavirin, producing sustained virologic response in more than half of patients with chronic infection, although more than half of those with genotype 1 failed to achieve that endpoint. Direct-acting antiviral drugs, including protease and polymerase inhibitors, arose from the characterization of viral enzymes as treatment targets. First-generation protease inhibitors telaprevir and boceprevir increased sustained virologic response rates in genotype 1 infection by approximately 20% to 30%, while safety, anemia, rash, cost, adherence, resistance, and drug interactions remained important limitations.

Hemodialysis therefore occupies a double position in the history of hepatitis C virus infection. It is a vulnerable environment in which transmission once occurred with disturbing frequency, but it is also a setting where disciplined hygiene, improved blood safety, molecular diagnosis, and antiviral treatment can change the course of disease. Its significance extends beyond the dialysis machine: infection can influence liver-related death, immune-mediated kidney injury, mental well-being, and the prospects of later kidney transplantation, making control of hepatitis C an essential part of long-term renal care.